These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17987225)

  • 41. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multimodal imaging approaches: PET/CT and PET/MRI.
    Pichler BJ; Judenhofer MS; Pfannenberg C
    Handb Exp Pharmacol; 2008; (185 Pt 1):109-32. PubMed ID: 18626801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving the accuracy of target volume delineation by combined use of computed tomography, magnetic resonance imaging and positron emission tomography in head and neck carcinomas.
    Chauhan D; Rawat S; Sharma MK; Ahlawat P; Pal M; Gupta G; Dewan A; Gupta M; Sharma S; Dodagoudar C; Pahuja A; Mitra S; Sharma SK
    J Cancer Res Ther; 2015; 11(4):746-51. PubMed ID: 26881512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
    Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
    Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Controlling type I error rate for fast track drug development programmes.
    Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L
    Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of positron emission tomography for drug development for heart failure.
    Papadimitriou L; Smith-Jones PM; Sarwar CM; Marti CN; Yaddanapudi K; Skopicki HA; Gheorghiade M; Parsey R; Butler J
    Am Heart J; 2016 May; 175():142-52. PubMed ID: 27179733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hybrid PET/MR imaging: physics and technical considerations.
    Shah SN; Huang SS
    Abdom Imaging; 2015 Aug; 40(6):1358-65. PubMed ID: 25985965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography.
    Zaidi H; Montandon ML; Slosman DO
    Med Phys; 2003 May; 30(5):937-48. PubMed ID: 12773003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiac hybrid imaging.
    Gaemperli O; Saraste A; Knuuti J
    Eur Heart J Cardiovasc Imaging; 2012 Jan; 13(1):51-60. PubMed ID: 22094239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Regulatory Framework for Approval of PET Drug in Korea: A Survey Report].
    Kurihara C; Inoue T
    Kaku Igaku; 2015 Nov; 52(4):341-52. PubMed ID: 27263269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines.
    Berding G; Banati RB; Buchert R; Chierichetti F; Grover VP; Kato A; Keiding S; Taylor-Robinson SD;
    Liver Int; 2009 May; 29(5):621-8. PubMed ID: 19413665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current and emerging imaging in relation to drug discovery in airways disease.
    King GG
    Pulm Pharmacol Ther; 2011 Oct; 24(5):497-504. PubMed ID: 21807109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results.
    Wetter A; Lipponer C; Nensa F; Beiderwellen K; Olbricht T; Rübben H; Bockisch A; Schlosser T; Heusner TA; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):256-62. PubMed ID: 23462678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical positron emission tomography/magnetic resonance imaging applications.
    von Schulthess GK; Kuhn FP; Kaufmann P; Veit-Haibach P
    Semin Nucl Med; 2013 Jan; 43(1):3-10. PubMed ID: 23178084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Zohydro approval by food and drug administration: controversial or frightening?
    Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
    Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hybrid imaging: clinical evidence, opportunities].
    Trencsényi G; Barna SK; Garai I
    Orv Hetil; 2015 Dec; 156(52):2110-5. PubMed ID: 26686747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Future direction of renal positron emission tomography.
    Szabo Z; Xia J; Mathews WB; Brown PR
    Semin Nucl Med; 2006 Jan; 36(1):36-50. PubMed ID: 16356795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
    Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
    Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.